Drug Type Small molecule drug |
Synonyms- |
Target |
Mechanism DNA inhibitors(DNA inhibitors), TOP1 inhibitors(DNA topoisomerase I inhibitors), DNA alkylating agents + [2] |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaCl2H6N2Pt |
InChIKeyWCLAIRSNZFYZAT-UHFFFAOYSA-N |
CAS Registry15663-27-1 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Small Cell Lung Cancer | Phase 2 | - | - |
Not Applicable | Recurrent ovarian cancer Second line | - | cjkwdypcxg(nnhnlqrosx) = The most common adverse effect of belotecan combined with platinum was hematologic toxicity, however it was tolerable prciijemoe (sflutkntdz ) | Positive | 20 May 2010 |